Two Sigma Advisers’s Creative Medical Technology CELZ Stock Holding History

Two Sigma Advisers’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-14,500	Closed	-$44.9K	–	2358
2024 Q3	$44.9K	Sell	14,500 -500	-3%	-$1.69K	﹤0.01%	2219
2024 Q2	$57.8K	Buy	15,000 +3,256	+28%	+$14.7K	﹤0.01%	2353
2024 Q1	$61.2K	Buy	+11,744	New	+$54.7K	﹤0.01%	2339

Other funds holding CELZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Advisers's CELZ Position: Q4 2024 in Review

Two Sigma Advisers sold out of Creative Medical Technology (CELZ) in Q4 2024, closing a stake of 14,500 shares — an estimated $44.9K sold.

Two Sigma Advisers first reported a position in CELZ in Q1 2024 and held it in 3 quarters. The position peaked at $61.2K in Q1 2024. 8 funds tracked by Wall St. Rank hold CELZ as of Q4 2024.

Two Sigma Advisers reported no remaining Creative Medical Technology position as of Q4 2024 after selling out during the quarter.
Two Sigma Advisers sold 14,500 Creative Medical Technology shares in Q4 2024, an estimated $44.9K.
Two Sigma Advisers first reported a position in Creative Medical Technology in Q1 2024 and held it in 3 quarters.
Two Sigma Advisers's Creative Medical Technology position peaked at $61.2K in Q1 2024.
8 funds tracked by Wall St. Rank held Creative Medical Technology as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.